MedTrace Logo

Effects of Inspiratory Muscle Training in Patients With Post COVID-19

NCT05231395 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-24

No results posted yet for this study

Summary

Coronavirus-2019 (COVID-19) is a new virus that emerged in December 2019 and spread quickly all over the world. Problems such as hypoxia, dyspnea, increased fatigue, decreased exercise capacity and respiratory muscle strength occur in COVID-19 patients.In addition, abnormalities in skeletal muscles due to systemic inflammation, mechanical ventilation, sedation and prolonged bed rest in hospital and intensive care patients cause decreased exercise capacity.

Conditions

Interventions

OTHER

Inspiratory Muscle Training Group

Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure. Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks. Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week.

OTHER

Control Group

Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program. Control group will be followed-up by telephone once a week

Sponsors & Collaborators

  • Gazi University

    lead OTHER

Principal Investigators

  • Başak KAVALCI KOL, Pt. MSc. · Gazi University

  • Ece BAYTOK, Pt. MSc. · Gazi University

  • Nilgün YILMAZ DEMİRCİ, Assoc.Prof · Gazi University

  • Meral BOŞNAK GÜÇLÜ, Prof. Dr. · Gazi University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-25
Primary Completion
2024-05-15
Completion
2024-05-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05231395 on ClinicalTrials.gov